New Parkinson's Disease Treatment A new Parkinson's Disease treatment is giving 69-year-old Bob Van Housen new freedom. Cleveland Clinic physician, Hubert Fernandez, MD, discusses the new approach. The treatment which pumps a medicated gel into Van Housen's small intestine helps him control symptoms. Van Housen was diagnosed with Parkinson's Disease 12 years ago. To learn more about the disease, visit bit.lyFrom:ClevelandClinicViews:768 3ratingsTime:02:20More inScience Technology See original here: New Parkinson's Disease Treatment - Video … Continue reading →

Dr Marvin's WHY this works so well! "I have seen more miracles in the first 3 months that I used this technology than in 50 years of traditional medicine." Norman Marvin, MD Pro 7 Leader, LifeVantage Dr. David Perlmutter's research on Parkinson treatment with Glutathione http://www.youtube.com Learn more about Protandim's natural science product featured on ABC Primetime News: renewmygenes.com Lifevantage is a publicly traded corporation based in Utah, USA with stock symbol LFVN.From:wealthycopyViews:380 3ratingsTime:01:05:39More inEntertainment Continued here: Dr Marvin's WHY this works so well! - Video … Continue reading →

Public release date: 24-Oct-2012 [ | E-mail | Share ] Contact: David Cameron david_cameron@hms.harvard.edu 617-432-0441 Harvard Medical School Scientists may have discovered why the standard treatment for Parkinson's disease is often effective for only a limited period of time. Their research could lead to a better understanding of many brain disorders, from drug addiction to depression, that share certain signaling molecules involved in modulating brain activity. A team led by Bernardo Sabatini, Takeda Professor of Neurobiology at Harvard Medical School, used mouse models to study dopamine neurons in the striatum, a region of the brain involved in both movement and learning. In people, these neurons release dopamine, a neurotransmitter that allows us to walk, speak and even type on a keyboard. When those cells die, as they do in Parkinson's patients, so does the ability to easily initiate movement. Current Parkinson's drugs are precursors of dopamine that are then converted into dopamine by cells in the brain. The flip side of dopamine dearth is dopamine hyperactivity. Heroin, cocaine and amphetamines rev up or mimic dopamine neurons, ultimately reinforcing the learned reward of drug-taking. Other conditions such as obsessive-compulsive disorder, Tourette syndrome and even schizophrenia may also be related to the … Continue reading →

ESPOO, FINLAND--(Marketwire - Oct 24, 2012) - ODM-101, a new levodopa product currently developed by Orion for the treatment of Parkinson's disease, has successfully completed Phase II Proof of Concept trial. The key results indicate that ODM-101 was more efficacious than the reference product Stalevo in the treatment of advanced Parkinson's disease patients. The study included more than 100 patients in Europe. Professor Claudia Trenkwalder, the Principal Investigator of the ODM-101 Proof of Concept study, comments: "This phase II study demonstrated that ODM-101 has potential to be significantly more effective than Stalevo in the daily treatment of Parkinson's disease patients with response fluctuations. ODM-101 reduced time periods during the day when patients do not have adequate treatment response. These benefits were possible without an increase in troublesome involuntary movements (dyskinesia)." Stalevo, a product of Orion's own pharmaceutical R&D, has been established by long-term clinical practice as a standard medication for advanced Parkinson's patients experiencing so-called end-of-dose wearing-off symptoms associated with levodopa therapy. Stalevo is an enhanced levodopa treatment containing three active substances in one tablet: levodopa and the enzyme inhibitors entacapone and carbidopa. Measured in overall sales of entacapone products in 2011, Orion is the world's leading manufacturer of Parkinson's … Continue reading →

Public release date: 24-Oct-2012 [ | E-mail | Share ] Contact: Marla Paul marla-paul@northwestern.edu 312-503-8928 Northwestern University CHICAGO --- In an early-stage breakthrough, a team of Northwestern University scientists has developed a new family of compounds that could slow the progression of Parkinson's disease. Parkinson's, the second most common neurodegenerative disease, is caused by the death of dopamine neurons, resulting in tremors, rigidity and difficulty moving. Current treatments target the symptoms but do not slow the progression of the disease. The new compounds were developed by Richard B. Silverman, the John Evans Professor of Chemistry at the Weinberg College of Arts and Sciences and inventor of the molecule that became the well-known drug Lyrica, and D. James Surmeier, chair of physiology at Northwestern University Feinberg School of Medicine. Their research was published Oct. 23 in the journal Nature Communications. The compounds work by slamming the door on an unwelcome and destructive guest -- calcium. The compounds target and shut a relatively rare membrane protein that allows calcium to flood into dopamine neurons. Surmeier's previously published research showed that calcium entry through this protein stresses dopamine neurons, potentially leading to premature aging and death. He also identified the precise protein involved … Continue reading →

By Rick Nauert PhD Senior News Editor Reviewed by John M. Grohol, Psy.D. on October 26, 2012 Researchers at Harvard Medical School may have solved the mystery of why the standard treatment for Parkinsons disease is often effective for only a limited period of time. Experts say their findings could lead to a better understanding of many brain disorders, from drug addiction to depression. Investigators used mouse models to study dopamine neurons in the striatum, a region of the brain involved in both movement and learning. In people, these neurons release dopamine, a neurotransmitter that allows us to perform tasks such as walking, speaking and even typing on a keyboard. When a person has Parkinsons the dopamine cells die and the ability to easily initiate movement is lost. Current Parkinsons drugs are precursors of dopamine that are then converted into dopamine by cells in the brain. On the other hand, dopamine hyperactivity is associated with drug-seeking behaviors as heroin, cocaine and amphetamines rev up or mimic dopamine neurons, ultimately reinforcing the learned reward of drug-taking. Conditions such as obsessive-compulsive disorder, Tourette syndrome and even schizophrenia may also be related to the misregulation of dopamine. In a current issue of Nature, … Continue reading →

North American Seminars, Inc. a national provider of physical therapy continuing education courses introduces Functional Techniques for the Evaluation and Treatment of Parkinson's Disease. Franklin, TN (PRWEB) October 26, 2012 This two-day intermediate level pt continuing education course provides an in-depth look at the evaluation and treatment of patients with Parkinson's disease. The most current evidence-based and advanced concepts in rehabilitation for the effective management of Parkinson's disease will be thoroughly discussed. This course enables the clinician to identify impairments and functional limitations of patients with Parkinson's disease and then implement an effective treatment plan to achieve optimal outcomes. An overview of common medications, surgical procedures and the effects they can have on rehabilitation are discussed in an interactive format. The scientific and clinical rationale for assessment and treatment strategies are thoroughly discussed in this physical therapy continuing education course. The interactive laboratory sessions throughout day two will enhance the information learned on integrative and functional treatment techniques. The techniques can be immediately applied to the clinical setting to promote positive treatment outcomes. The case studies presented enable the clinician to perform effective evaluations and to develop appropriate rehabilitation programs. Proper documentation and goal-writing guidelines are also discussed. The clinician … Continue reading →